Inhibiton Therapeutics' Researcher to Present at the Ehrlich II, 2ND World Conference...

Inhibiton Therapeutics' Researcher to Present at the Ehrlich II, 2ND World Conference on "Magic Bullets"

CENTENNIAL, Colo.--(Business Wire)--
Inhibiton Therapeutics, Inc. (OTCBB: IHBT) announced today that
the principal researcher for its ICA-1 compound, Dr. Mildred
Acevedo-Duncan, will present the work for ICA-1 entitled "PKC-i
inhibition by ICA-1 reduces the cell proliferation of Neuroblastoma"
at the Ehrlich II, World Conference on Magic Bullets in Nurnberg,
Germany on October 3-5, 2008.

The ICA-1 compound has demonstrated more exacting specificity of
protein kinase C-iota and not of proteins that are closely related to
PKC-iota. These results demonstrate greater promise for the
development of a targeted therapy. Research being funded by the
Company has shown that the ICA-1 compound has been effective in
laboratory in-vitro testing in various cancer cell lines. This
research has demonstrated that inhibition of the enzyme protein kinase
C-iota is a promising means to prevent and treat certain cancers
through development of a targeted therapy.

Previously announced laboratory testing has shown that ICA-1 was
effective in blocking BE(2)C neuroblastoma cells finding and that
lower concentrations of ICA-1 were more efficacious in inhibiting the
proliferation of 64% and 53% of the neuroblastoma cells when compared
to control groups. The effects of ICA-1 on breast cancer cells have
also obtained promising results. ICA-1 was effective in reducing the
proliferation of MDA-MB-468 breast cancer cells by 83% compared to
controls when incubated with the drug for 48 hours at clinical
concentrations. For MCF-7 breast cancer cells, ICA-1 was effective in
reducing the proliferation by 32% compared to controls when treated
with the drug for 24 hours.

These results indicate that ICA-1 has promising results for
further in-vitro studies as well as future in-vivo studies for the
potential treatment of both neuroblastoma and breast cancer.

About the Ehrlich II, World Conference on Magic Bullets

According to its website address www.ehrlich-2008.org "The
conference is dedicated to Paul Ehrlich and is held to commemorate the
100th anniversary of his Nobel Prize award. In his Nobel Lecture on
December 11th, 1908, Paul Ehrlich laid out the foundation of
chemotherapy and the use of drugs to cure patients. He coined the term
Magic Bullets and this term has remained in science as well as in the
lay world for particularly important and clinically efficacious drugs.

"At this conference the discovery, development and successful use
of Magic Bullets in clinical medicine will be presented and vividly
discussed. Particular reference is given to PK/PD - relationships to
develop and use Magic Bullets in patients more rationally by use of
the modern methods of individualization of drug therapy.

"The conference is aimed to bring together clinical and
pharmacological scientists."

About Inhibiton Therapeutics, Inc.

Inhibiton Therapeutics, Inc. is a nominally capitalized
development stage company focused on biotechnology research,
development and potential commercialization of technologies and
products for new cancer therapeutic agents and cancer fighting drugs
called targeted therapies. The initial focus of the Company's research
is a protocol to investigate the effect of PKC isozymes on the
regulation of various cancer cells including brain and breast cancer.
Inhibiton began funding this research in September 2004.

The statements included in this press release concerning
predictions of economic performance and management's plans and
objectives constitute forward-looking statements made pursuant to the
safe harbor provisions of Section 21E of the Securities Exchange Act
of 1934, as amended, and Section 27A of the Securities Act of 1933, as
amended. These statements involve risks and uncertainties that could
cause actual results to differ materially from the forward-looking
statements. Any statement containing words such as "believes"
"anticipates" "plans" or "expects" and other statements which are not
historical facts contained in this release are forward-looking, and
these statements involve risks and uncertainties and are based on
current expectations. Consequently, actual results could differ
materially from the expectations expressed in these forward-looking
statements. Reference is made to the Company's filings with the
Securities and Exchange Commission for a more complete discussion of
such risks and uncertainties.

Inhibiton Therapeutics, Inc.
Thomas B. Olson, 303-796-8949
Corporate Secretary

Copyright Business Wire 2008